ArticleDermatology reports2025
The humanistic burden of atopic dermatitis in Greece: a cross-sectional study.
Article in Dermatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world efficacy and safety of dupilumab in the treatment of head and neck atopic dermatitis: a retrospective cohort study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to evaluate the quality of life (QoL) and psychosocial burden in adult Greek patients with atopic dermatitis (AD) using validated tools and to investigate factors that influence AD's humanistic burden. This observational, cross-sectional study was conducted in Greece (January-September 2023) with 150 adult members of the patient association "Epidermia", all diagnosed with AD. Data was collected through a structured questionnaire, including socio-demographic details, clinical history, AD severity (using the Patient-Oriented Eczema Measure [POEM]), QoL, sleep disorders, and psychological health. Based on POEM scores, 11% of participants had clear/almost clear skin, 27% had mild eczema, 51% had moderate eczema, and 12% had severe/very severe eczema. AD had a moderate or very/extremely large impact on QoL for 29% and 42% of participants, respectively. Insomnia affected 55%, while 31% had mild anxiety, 23% had moderate/severe anxiety, 10% had moderate depression, and 8% had moderately severe/severe depression. AD severity was associated with reduced QoL and higher rates of insomnia, anxiety, and depression. Our study highlights significant associations between AD severity, QoL, and psychosocial factors, emphasizing the need for comprehensive management strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.